168 articles with Flexion Therapeutics
Flexion Therapeutics Enrolls First Patient in Study Evaluating the Pharmacokinetics and Safety of ZILRETTA in Osteoarthritis of the Shoulder and Hip
Known as the “"HIP" study, the randomized, open-label, Phase 2 trial is expected to recruit approximately 48 patients in total, including 24 patients with OA of the shoulder and 24 patients with OA of the hip.
Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee
As part of the deal, Flexion will make an upfront payment of $2 million to GeneQuine and may incur milestone payments of up to $8.7 million through Phase 2 proof of concept (PoC).
Dr. Kelley will assumes responsibility for all medical matters at Flexion, including Medical Affairs, Clinical Research and Clinical Operations.
Biotech companies have a number of pivotal challenges in going from a promising compound to commercially viable products.
Flexion Therapeutics Enrolls First Patient in Phase II Pharmacokinetics and Safety Study of ZILRETTA (Triamcinolone Acetonide Extended-Release Injectable Suspension) in Bilateral Osteoarthritis of the Knee
The randomized, open-label, Phase 2 study is expected to enroll approximately 24 patients.
On Oct. 6, the FDA approved Flexion Therapeutics' Zilretta for osteoarthritis knee pain and is now in the middle of launching the drug and installing its commercial operations.
Flexion Therapeutics Announces Full Commercial Launch and Nationwide Availability of ZILRETTA (Triamcinolone Acetonide Extended-Release Injectable Suspension)
Flexion has hired and trained more than 100 field sales representatives, known as Musculoskeletal Business Managers, who are now deployed across the country.
Fluxion Biosciences today announced that it has signed a distribution agreement with Harvard Biosciences.
The Company reported a net loss of $34.2 million for the third quarter of 2017, compared to a net loss of $17.8 million for the same period of 2016.
Flexion Therapeutics Highlights Two Clinical Data Presentations at the 2017 American College of Rheumatology Annual Meeting
Zilretta is a non-opioid medicine that employs Flexion’s proprietary microsphere technology.
A live webcast of the conference call can also be accessed through the "Investors" tab on the Flexion Therapeutics website.
10/25/2017A look at FDA head Scott Gottlieb's career so far.
The approval has made Flexion an even bigger target of acquisition rumors.
Flexion To Hold Conference Call At 8:00 A.M. ET To Discuss Recent FDA Approval Of ZILRETTA (Triamcinolone Acetonide Extended-Release Injectable Suspension)